Donate now, support IFFGD

My Cart | Register | Sign In

Header Image

Industry News

This page lists treatment news from IFFGD Industry Council Members. No endorsement is intended or implied.

What's in the news

Teduglutide

April 3, 2014 – Participants are being sought for a global clinical study evaluating, in routine settings, long-term data on safety of teduglutide and on the natural history of short bowel syndrome (SBS) in patients of all ages. Learn more

Lubiprostone (Amitiza)

February 6, 2014 - Swiss regulations relaxed for prescribing Amitiza to patients with chronic ideopathic constipation (CIC). Learn more 

Teduglutide

January 8, 2014 – Participants are being sought for a multi-center (US and Europe) clinical study evaluating safety and efficacy of teduglutide in treating children with short bowel syndrome (SBS). Learn more

Gattex

November 13, 2013 – The FDA has accepted for consideration a supplemental New Drug Application (sNDA) for Gattex (teduglutide), to include results from 2-year study for long term use in patients with short bowel syndrome (SBS). Learn more 

Linaclotide (Linzess/Constella)

June 13, 2013 – Linaclotide is now available in Europe (branded as Costella in the EU) to treat irritable bowel syndrome with constipation (IBS-C)Learn more

Relistor

June 11, 2013 – Salix announced that the FDA will be holding an advisory committee to review Salix's Supplemental New Drug Application, which seeks to extend the use of this drug to include patients who are taking opioids to treat chronic pain.

Relistor was approved in the United States in 2008 for short term treatment of opioid-induced constipation, in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. It has also received approval for this indication in other countries.

Elobixibat

May 2, 2013 – Ferring Pharmaceuticals has begun phase III clinical trials of elobixibat. The studies are testing the efficacy and safety of repeated daily doses of elobixibat versus placebo.

Elobixibat is a first-in-class compound currently under investigation for treatment of chronic idiopathic constipation (CIC), and for irritable bowel syndrome with constipation (IBS-C). Learn more

Rifaximin

February 21, 2012 – Salix Pharmaceuticals announced the initiation of a new Phase 3 study to evaluate the efficacy and safety of repeat treatment with Xifaxan (rifaximin) for irritable bowel syndrome with diarrhea (IBS-D). Learn more

Solesta

September 6, 2011 – Oceana Therapeutics today announced the U.S. launch of Solesta, a significant new treatment option for patients with fecal (bowel) incontinence for whom conservative therapies have failed. Learn more

Metozolv

September 8, 2009 – The FDA has granted marketing approval for the drug metoclopramide (Metozolv) 5mg and 10 mg orally disintegrating tablets. The drug is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults and the treatment of symptomatic documented GERD in adults who do not respond to conventional therapy. Therapy should not exceed 12 weeks in duration. Important safety information should be discussed with your doctor. Learn more

Kapidex/Dexilant

January 30, 2009 – The U.S. Food and Drug Administration (FDA) today approved KAPIDEX™ (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. KAPIDEX (30 mg and 60 mg) is the first proton pump inhibitor (PPI) with a Dual Delayed Release™ (DDR) formulation designed to provide two separate releases of medication. Learn more

Kapidex changed its name to Dexilant in April 2010. 

 

 

Last modified on April 3, 2014 at 05:31:45 PM